Evidence map›Paper›PMID 33973071›Full record

ArticleEuropean journal of pediatrics2021

Sodium-containing versus sodium-trace preparations of IVIG for children with Kawasaki disease in the acute phase.

Takanori Suzuki, Nobuaki Michihata, Shotaro Aso, Tetsushi Yoshikawa, Kazuyoshi Saito, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Shaanxi Provincial Diagnosis and Treatment Center of Kawasaki Disease.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Takanori SuzukiDepartment of Pediatric Cardiology, Aichi Children's Health and Medical Center, Aichi, Japan.
Nobuaki MichihataDepartment of Health Services Research, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan. michihata@m.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0003-3091-114X
Shotaro AsoDepartment of Biostatistics & Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tetsushi YoshikawaDepartment of Pediatrics, Fujita Health University, Aichi, Japan.
Kazuyoshi SaitoDepartment of Pediatrics, Fujita Health University, Aichi, Japan.
Hiroki MatsuiDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Kiyohide FushimiDepartment of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.
Hideo YasunagaDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Fujita Health University · JPUniversity of Tokyo Health Sciences · JPDepartment of Health Services · NPThe University of Tokyo · JPTokyo Medical and Dental University · JP

Funding

Ministry of Education, Culture, Sports, Science and Technology 20H03907Ministry of Health, Labour and Welfare 19AA2007 and 20AA2005
6 · The paper itself

Abstract

Kawasaki disease (KD) is an acute systemic vasculitis that most commonly causes acquired cardiac disease in children in developed countries. The most highly recommended treatment for KD is 2 g/kg intravenous immunoglobulin (IVIG). There are two types of IVIG, sodium-containing (high-Na) and sodium-trace (low-Na) preparations. However, few studies have compared the effects of these two preparations for superiority. The purpose of this study was to compare outcomes between high and low-Na IVIG preparations in KD children using a national inpatient database in Japan. We used the Diagnostic Procedure Combination database to identify KD patients treated with IVIG between 2010 and 2017. We identified those receiving high and low-Na preparations of IVIG as an initial treatment. Outcomes included proportion of coronary artery abnormalities (CAA), IVIG resistance, adverse effects, length of stay, and medical cost. Propensity score-matched analyses were conducted to compare the outcomes between the two groups. Instrumental variable analyses were performed to confirm the results. We identified 42,345 patients with KD. There were significant differences in proportions of CAA (2.8% vs. 3.2%; p = 0.031) and IVIG resistance (17% vs. 18%, p = 0.001) between the two groups. However, there were no significant differences in length of stay or medical cost. The instrumental variable analysis confirmed the same results as the propensity score analysis.Conclusion: The present study suggests that high-Na IVIG is potentially effective for reducing the proportion of CAA in KD patients. Prospective studies are warranted to confirm the effectiveness observed in this study. What is Known: • For treatments of Kawasaki Disease in acute phase, intravenous immunoglobulin have been the most recommended to reduce fever early and prevent complications of coronary artery abnormalities. There are two types of IVIG preparations, sodium-containing IVIG and sodium-trace IVIG. However, few studies have performed comparisons to determine which preparation of IVIG is superior. What is New: • The present findings suggest that high-Na IVIG is associated with reductions in the proportions of CAAs and IVIG resistance in KD patients.

Indexed as

Coronary Artery DiseaseMucocutaneous Lymph Node SyndromeChildFeverHumansImmunoglobulins, IntravenousInfantRetrospective StudiesSodiumImmunoglobulins, IntravenousSodiumCoronary artery abnormalitiesIntravenous immunoglobulinKawasaki diseaseSodium concentration

Identifiers

PMID33973071
OpenAlexW3130937051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.